Rumored negative data leak drives 30% PYXS plunge on high volume
Rumored negative MICVO data leak drives 30% PYXS plunge on high volume
- PYXS fell ~30-32% intraday on Aug 11 2026 from $3.83 close to lows near $1.90 with massive volume (>4-7M shares) and multiple LULD volatility halts
- Biotech traders on X widely attribute move to intraday leak of disappointing safety/efficacy data for lead ADC micvotabart pelidotin (MICVO) in HNSCC trial
- Speculation centers on toxicity issues with ADC warhead/payload falling off target; compared to prior PLRX safety data leak that preceded trial halt
- Company is single-asset focused on MICVO; updated Phase 1 monotherapy data was expected mid/Fall 2026 following earlier preliminary results that disappointed some on small sample size
- Recent positive catalysts included $114M private placement (Jun 2026) and bullish analyst initiations (e.g. Wells Fargo Overweight Aug 3) fueling prior run-up
- No official company press release or confirmation; earnings scheduled for Aug 13 with no direct tie to today's move
- After-hours recovery seen in some quotes but regular session drop reflects acute retail/biotech trader reaction to rumor
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.